Trobalt
retigabine
Table of contents
Overview
The marketing authorisation for Trobalt has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Trobalt
|
| Agency product number |
EMEA/H/C/001245
|
| Active substance |
retigabine
|
| International non-proprietary name (INN) or common name |
retigabine
|
| Therapeutic area (MeSH) |
Epilepsy
|
| Anatomical therapeutic chemical (ATC) code |
N03AX21
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Glaxo Group Limited
|
| Revision |
12
|
| Date of issue of marketing authorisation valid throughout the European Union |
27/03/2011
|
| Contact address |
Glaxo Group Limited
980 Great West Road Brentford Middlesex TW8 9GS United Kingdom |
Product information
19/07/2018 Trobalt - EMEA/H/C/001245 - IAIN/0043
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiepileptics
Therapeutic indication
Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.